Wangshuzhen

Dr. Wang has a background in Biological Science,  completed her PhD in Microbiology and Biochemical Pharmacy, and joined China Pharmaceutical University in July 2008. Her current research field includes but not limited to the discovery and validation of new drug targets in liver diseases. 

1. Han Y, Gao Q, Xu Y, Chen K, Li R, Guo W, Wang S*. Cysteine sulfenylation contributes to liver fibrosis via the regulation of EphB2-mediated signaling. Cell Death Dis. 2024 Aug 20;15(8):602.

2. Han Y, Song H, Li Y, Li R, Chen L, Gao B, Chen Y*, Wang S*. The combination of tetracyclines effectively ameliorates liver fibrosis via inhibition of EphB1/2. Int Immunopharmacol. 2024 Jan 5;126:111261. 

3. Li R, Zhang D, Han Y, Chen K, Guo W, Chen Y*, Wang S*. Neddylation of EphB1 regulates its activity and associates with liver fibrosis. Int J Mol Sci. 2023 Feb 8;24(4):3415.

4. Chen K, Guo W, Li R, Han Y, Gao Q, Wang S*. Demethylzeylasteral attenuates hepatic stellate cell activation and liver fibrosis by inhibiting AGAP2 mediated signaling. Phytomedicine. 2022 Oct;105:154349.

5. Dacol EC, Wang S, Chen Y, Lepique AP. The interaction of SET and protein phosphatase 2A as target for cancer therapy. Biochim Biophys Acta Rev Cancer. 2021 Aug;1876(1):188578.

6. Chen X, Zhang D, Wang Y, Chen K, Zhao L, Xu Y, Jiang H*, Wang S*. Synergistic antifibrotic effects of miR-451 with miR-185 partly by co-targeting EphB2 on hepatic stellate cells. Cell Death Dis. 2020 May 28;11(5):402. 

81473126, National Natural Science Foundation of China, Wang, Shuzhen (PI)

81872924, National Natural Science Foundation of China, Wang, Shuzhen (PI) 

2016 333-Project Talent of Jiangsu Province

2015 Six Talent Peaks Project in Jiangsu Province